Literature DB >> 20582589

The effect of radiotherapy on NKT cells in patients with advanced head and neck cancer.

Kouichi Kobayashi1, Yuriko Tanaka, Shigetoshi Horiguchi, Shouji Yamamoto, Nakayama Toshinori, Akira Sugimoto, Yoshitaka Okamoto.   

Abstract

BACKGROUND: Cancer immunotherapy with NKT cells is a potential new treatment strategy for advanced head and neck cancer. NKT cell therapy is promising due to its unique anti-tumor activity and higher degree of safety compared to current therapies. Radiotherapy is indispensable as a standard treatment for advanced head and neck cancer. To elucidate the possibility of using NKT cells as an adjuvant immunotherapy with radiotherapy, we examined the effect of radiotherapy on NKT cells in patients with head and neck cancer.
METHODS: The number, IFN-gamma production and proliferation capacity of NKT cells were analyzed before and after 50 Gy radiation therapy in 12 patients with stage IV head and neck squamous cell carcinoma. The cytotoxic activity of NKT cells was examined in vitro.
RESULTS: The number of NKT cells in the blood varied widely between patients. After radiation therapy, the population of CD3 T cells decreased significantly, while the NKT cell population remained stable. The number of NKT cells was the same after radiation therapy as before. IFN-gamma production from NKT cells collected just after radiotherapy was impaired after stimulation with exogenous ligand, but the proliferative responses of these NKT cells was enhanced in comparison to those collected before radiation therapy. Furthermore, the proliferated NKT cells displayed a significant level of anti-tumor activity.
CONCLUSION: NKT cells are relatively resistant to radiation and might therefore be suitable for adjuvant immunotherapy to eradicate remnant cancer cells in patients who have undergone radiation therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20582589     DOI: 10.1007/s00262-010-0877-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  7 in total

Review 1.  Presumed guilty: natural killer T cell defects and human disease.

Authors:  Stuart P Berzins; Mark J Smyth; Alan G Baxter
Journal:  Nat Rev Immunol       Date:  2011-02       Impact factor: 53.106

2.  Natural killer T cells: drivers or passengers in preventing human disease?

Authors:  Stuart P Berzins; David S Ritchie
Journal:  Nat Rev Immunol       Date:  2014-08-08       Impact factor: 53.106

Review 3.  Targeting Natural Killer T Cells in Solid Malignancies.

Authors:  Zewde Ingram; Shriya Madan; Jenoy Merchant; Zakiya Carter; Zen Gordon; Gregory Carey; Tonya J Webb
Journal:  Cells       Date:  2021-05-27       Impact factor: 6.600

4.  Hepatic irradiation persistently eliminates liver resident NK cells.

Authors:  Ryosuke Nakano; Masahiro Ohira; Takuya Yano; Yuki Imaoka; Yuka Tanaka; Hideki Ohdan
Journal:  PLoS One       Date:  2018-06-13       Impact factor: 3.240

Review 5.  Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer.

Authors:  Mariko Takami; Fumie Ihara; Shinichiro Motohashi
Journal:  Front Immunol       Date:  2018-09-07       Impact factor: 7.561

Review 6.  CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond.

Authors:  Lisa A King; Roeland Lameris; Tanja D de Gruijl; Hans J van der Vliet
Journal:  Front Immunol       Date:  2018-07-02       Impact factor: 7.561

7.  Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).

Authors:  Minli Niu; Stephanie E Combs; Annett Linge; Mechthild Krause; Michael Baumann; Fabian Lohaus; Nadja Ebert; Ingeborg Tinhofer; Volker Budach; Jens von der Grün; Franz Rödel; Anca-Ligia Grosu; Gabriele Multhoff
Journal:  Radiat Oncol       Date:  2021-07-31       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.